Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

Fate Therapeutics (FATE) Misses Q3 EPS by 6c

November 1, 2018 5:03 PM EDT

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.31), $0.06 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.87 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

... More